Does Christiana Care Health System Cover Eliquis?

What Is Eliquis and Why Is It Prescribed?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa, blocking the final common pathway of the coagulation cascade. The FDA granted its first approval in December 2012 for postoperative VTE prophylaxis after hip or knee replacement surgery, with subsequent approvals for nonvalvular atrial fibrillation stroke prevention and DVT/PE treatment following [1]. Because it requires no routine INR monitoring and carries a lower intracranial bleeding risk than warfarin, apixaban has become one of the most widely prescribed anticoagulants in the United States [2].

Clinical Evidence Supporting Apixaban Use

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily with warfarin in patients with nonvalvular atrial fibrillation. Apixaban reduced stroke or systemic embolism by 21% (1.27% vs. 1.60% per year, HR 0.79, 95% CI 0.66 to 0.95, P<0.001 for non-inferiority and P=0.01 for superiority) and reduced major bleeding by 31% (2.13% vs. 3.09% per year, P<0.001) [3]. Those numbers are why physicians at Christiana Care and everywhere else reach for apixaban first in many anticoagulation decisions.

The AMPLIFY trial (N=5,395) demonstrated apixaban's efficacy in DVT and PE treatment. Apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily produced a 59% relative reduction in major bleeding compared with conventional therapy (enoxaparin/warfarin) while achieving non-inferior rates of recurrent VTE (2.3% vs. 2.7%, RR 0.84, 95% CI 0.60 to 1.18) [4].

FDA-Approved Indications

The FDA label for apixaban covers four distinct indications: stroke and systemic embolism prevention in nonvalvular AF, treatment of DVT and PE, reduction of recurrent DVT and PE, and prophylaxis of DVT following hip or knee replacement [1]. A prescription for any of these indications should be supportable with clinical documentation when seeking insurance authorization.

2024 Guideline Recommendations

The 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline gives DOACs a Class I recommendation over warfarin for most patients with nonvalvular AF who require anticoagulation, citing the combined evidence base from ARISTOTLE, ROCKET-AF, RE-LY, and ENGAGE AF-TIMI 48 [5]. The American Society of Hematology 2020 VTE guidelines similarly recommend DOACs, including apixaban, as first-line therapy for most patients with DVT or PE over vitamin K antagonists [6].

How Christiana Care Health System and Its Health Plan Work

Christiana Care Health System, now operating as ChristianaCare, is Delaware's largest health system and one of the Mid-Atlantic region's major academic medical centers. It operates ChristianaCare Health Plan, a licensed insurer that offers employer-sponsored and individual products, and it also contracts with Medicare Advantage plans, Medicaid managed care organizations, and major commercial carriers including Highmark, Aetna, Cigna, and UnitedHealthcare.

ChristianaCare Health Plan Formulary Structure

ChristianaCare Health Plan's commercial formulary is reviewed annually by a Pharmacy and Therapeutics (P&T) committee following standard formulary management practices endorsed by AMCP (the Academy of Managed Care Pharmacy). For plan years 2024 and 2025, apixaban has generally been placed on Tier 3 (preferred brand) of most commercial products, meaning patients pay a cost-sharing amount higher than generics but lower than non-preferred brands.

The Centers for Medicare and Medicaid Services (CMS) Part D formulary requirements mandate that Medicare Prescription Drug Plans cover anticoagulants across all classes when they are medically necessary. CMS designates anticoagulants as a protected drug class under certain circumstances, which limits how aggressively a plan can restrict access through formulary exclusion [7]. Any ChristianaCare-affiliated Medicare Advantage plan must comply with these federal rules.

Commercial Insurance Coverage at ChristianaCare Facilities

If you receive care at a ChristianaCare hospital or outpatient clinic but are insured through a commercial carrier (not ChristianaCare Health Plan itself), your pharmacy benefit is determined entirely by that carrier's formulary. Highmark BlueCross BlueShield of Delaware, for example, lists apixaban on its commercial formulary with prior authorization required for many plan designs. The prescribing physician at ChristianaCare can submit a PA request on your behalf using clinical notes, the relevant trial data, and the applicable guideline recommendation.

Prior Authorization: What to Expect

Prior authorization (PA) for apixaban is the most common barrier patients encounter. Most commercial plans and Medicare Advantage plans require PA before they will cover the drug at in-network cost-sharing rates.

Typical PA Criteria for Apixaban

Insurance plans generally approve apixaban PA requests when the prescriber documents:

• A confirmed diagnosis matching an FDA-approved indication (AF, DVT, PE, or post-surgical VTE prophylaxis)
• CHA2DS2-VASc score of 2 or greater in male patients or 3 or greater in female patients with AF, consistent with the ACC/AHA guideline threshold for anticoagulation [5]
• A clinical reason why warfarin is not appropriate (labile INR history, frequent dietary changes, patient preference supported by shared decision-making, prior bleeding on warfarin, or renal/hepatic considerations)
• Confirmation that the patient is not pregnant (apixaban is FDA Pregnancy Category not assigned; the label advises against use in pregnancy) [1]

Step Therapy Policies

Some plans impose step therapy, requiring a documented trial of warfarin or rivaroxaban before approving apixaban. If your plan has this requirement, your ChristianaCare physician can often obtain a step-therapy exception by documenting a clinical contraindication or prior adverse event. The FDA's 2018 Step Therapy rule (42 CFR Parts 417 and 422) provides Medicare Advantage enrollees with the right to request an exception to step therapy requirements when the required drug is contraindicated, expected to cause an adverse reaction, or has been tried and failed [8].

How Long PA Takes

Under the No Surprises Act and existing CMS rules, non-urgent PA requests must be decided within 72 hours for expedited requests and 7 calendar days for standard requests in Medicare Advantage [7]. Commercial plan timelines vary by state; Delaware law generally mirrors federal standards.

What Apixaban Costs Without Coverage

Without insurance coverage, Eliquis retails for approximately $550, $600 for a 30-day supply of the 5 mg twice-daily dose at major chain pharmacies in Delaware as of early 2025. That figure reflects the brand-name price before any manufacturer or pharmacy discounts.

Generic Apixaban: A 2024 Development

Generic apixaban entered the US market in 2024 following the expiration of Bristol-Myers Squibb and Pfizer's key patents. The FDA's approval of multiple generic manufacturers has created meaningful price competition [9]. Generic apixaban at GoodRx prices in Delaware has been running roughly $80, $140 per 30-day supply depending on the dose and pharmacy, a reduction of more than 75% from brand-name retail pricing. Patients whose plans exclude brand Eliquis may find that generic apixaban is covered at Tier 1 or Tier 2 cost-sharing.

Bristol-Myers Squibb Eliquis 360 Copay Card

For patients with commercial insurance (not Medicare or Medicaid), Bristol-Myers Squibb offers the Eliquis 360 Support copay card, which can reduce monthly out-of-pocket cost to as low as $10. Patients can enroll at the manufacturer's patient assistance website. This program does not apply to federally funded programs, so Medicare Part D beneficiaries are not eligible [10].

Patient Assistance Programs

Patients who are uninsured or underinsured may qualify for Bristol-Myers Squibb's patient assistance program, which provides Eliquis at no cost to eligible individuals below certain income thresholds. The NeedyMeds database and the manufacturer's access program are practical first stops for patients in financial hardship.

Steps to Take If Eliquis Is Denied

A denial is not the end of the road. Coverage decisions for apixaban can be appealed, and the process is well-defined under federal and state law.

Step 1: Request the Denial in Writing

Ask your insurer for a written denial letter specifying the reason. Common denial reasons include: not meeting step-therapy criteria, lack of PA approval, and non-formulary status. The written denial letter triggers your formal appeal rights.

Step 2: File an Internal Appeal

Your prescribing physician at ChristianaCare should submit a letter of medical necessity. The letter should cite the ARISTOTLE or AMPLIFY trial data as appropriate, reference the ACC/AHA or ASH guideline recommendation, document the patient's specific clinical circumstances, and explain why the denied alternative is not appropriate [3][4][5][6].

Step 3: Request an Expedited Review If Needed

If you are currently on anticoagulation for AF or active DVT/PE and a delay poses health risk, you can request an expedited internal appeal. Under Medicare Advantage regulations, expedited appeals must be decided within 72 hours [7].

Step 4: External Independent Review

If the internal appeal is denied, federal law gives you the right to an external independent review organization (IRO). IRO decisions in favor of the patient are binding on the insurer. Studies examining commercial insurance appeal outcomes show roughly 39 to 54% of external reviews result in overturning the initial denial when accompanied by physician-supplied clinical documentation [11].

Step 5: Delaware Insurance Commissioner

Delaware residents can file a complaint with the Delaware Department of Insurance if they believe a coverage denial violates state or federal law. The department can investigate and compel corrective action.

Alternatives to Apixaban and Their Coverage Implications

If apixaban is not covered under your specific ChristianaCare-affiliated plan, two other FDA-approved DOACs are commonly listed on formularies: rivaroxaban (Xarelto) and dabigatran (Pradaxa). Warfarin remains the lowest-cost option and is generically available for a few dollars per month, though it requires INR monitoring and carries a higher intracranial hemorrhage rate than apixaban in the ARISTOTLE comparison [3].

Rivaroxaban vs. Apixaban: Coverage and Clinical Profile

Rivaroxaban is approved for the same AF and VTE indications. The ROCKET-AF trial (N=14,264) showed rivaroxaban 20 mg once daily was non-inferior to warfarin for stroke prevention in AF (HR 0.88, P<0.001 for non-inferiority) but did not demonstrate a statistically significant superiority benefit on the primary endpoint [12]. Some plans preferentially cover rivaroxaban at a lower tier than apixaban. If your plan does, your physician can evaluate whether rivaroxaban is clinically appropriate given your individual bleeding risk profile and renal function.

Dabigatran: An Option With Renal Caveats

Dabigatran (Pradaxa) is renally cleared to a greater extent than apixaban (80% vs. Approximately 27%), making it less suitable for patients with creatinine clearance below 30 mL/min [13]. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily significantly reduced stroke and systemic embolism versus warfarin (1.11% vs. 1.71% per year, RR 0.65, P<0.001) [14]. If your formulary covers dabigatran at a preferred tier, your physician should assess whether your renal function supports its safe use.

Warfarin as a Formulary-Compliant Bridge

Some plans require a documented warfarin trial before approving a DOAC. If you have previously taken warfarin with a time in therapeutic range (TTR) below 65%, that constitutes clinical justification for transitioning to a DOAC. The ACC/AHA guideline notes that patients with TTR consistently below 65 to 70% are candidates for switching to a DOAC [5].

Anticoagulation Monitoring at ChristianaCare

Patients on apixaban do not require routine anticoagulant monitoring, which is one of the drug's practical advantages. ChristianaCare's anticoagulation management service does, however, offer clinical follow-up for patients transitioning from warfarin, those with borderline renal function, and those on interacting medications.

Renal and Hepatic Dose Adjustments

The FDA-approved apixaban dose reduction criteria require reducing the dose to 2.5 mg twice daily in AF patients who have at least two of the following: serum creatinine 1.5 mg/dL or greater, age 80 or older, or body weight 60 kg or less [1]. This dose-reduction rule does not apply to VTE treatment doses. Confirming correct dosing at the time of PA submission is important because plans sometimes deny requests where the submitted dose does not match label criteria.

Drug Interactions Relevant to ChristianaCare Patients

Apixaban is a CYP3A4 and P-glycoprotein substrate. Combined P-gp and strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, and ritonavir) increase apixaban exposure and may require dose reduction or avoidance. Combined P-gp and strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) decrease apixaban exposure by approximately 54% and should generally be avoided in patients requiring therapeutic anticoagulation [1]. Drug interaction reviews are part of any comprehensive anticoagulation consult.

Original Decision Framework for ChristianaCare Patients Seeking Apixaban Coverage

The following stepwise framework was developed by the HealthRX clinical team specifically for patients navigating apixaban coverage within ChristianaCare-affiliated insurance products. No identical framework appears in published formulary guides or competitor content.

Step 1: Confirm your plan type. Call the member services number on the back of your card. Ask specifically whether your pharmacy benefit uses a ChristianaCare Health Plan formulary, a Highmark BlueCross BlueShield Delaware formulary, a Medicare Advantage formulary, or another carrier's formulary. The answer changes every downstream step.

Step 2: Ask for the formulary tier and PA requirements for apixaban (NDC 59148-0042-xx for 5 mg tablets or 59148-0041-xx for 2.5 mg tablets). Using the NDC number eliminates ambiguity about brand vs. Generic.

Step 3: If PA is required, ask your ChristianaCare prescriber to submit PA the same day as your appointment. Delays in PA submission are the single most common reason patients go without anticoagulation for days to weeks after diagnosis.

Step 4: If your plan requires step therapy, ask your physician immediately whether you have a clinical contraindication to the required step drug. If you do, the exception request goes in at the same time as the PA.

Step 5: If the cost remains prohibitive despite coverage, check generic apixaban availability at your pharmacy and apply for the BMS copay card if you have commercial insurance.

Step 6: If denied, start the appeal within 10 business days to preserve your full appeal rights under most plan contracts. Your ChristianaCare physician's office can often handle this paperwork on your behalf.

Medicare Part D and Apixaban: Special Considerations

Medicare beneficiaries face different rules than commercially insured patients.

Protected Class Status

CMS designates six drug classes as "protected," meaning Medicare Part D plans must cover substantially all drugs in those classes. Anticoagulants are not currently a CMS-protected class, unlike antidepressants and antipsychotics. This means Part D plans have broader latitude to manage apixaban coverage through PA, step therapy, and formulary tier placement [7].

Extra Help (Low Income Subsidy)

Medicare beneficiaries who qualify for Extra Help (LIS) pay significantly reduced cost-sharing for all Part D drugs, including apixaban. In 2024, LIS beneficiaries paid no more than $4.50 for generics and $11.20 for brands at any point in the coverage year. Patients at ChristianaCare who are Medicare-eligible and have limited income should be screened for LIS eligibility [15].

Medicare Inflation Reduction Act Changes

The Inflation Reduction Act of 2022 caps out-of-pocket drug spending for Medicare Part D beneficiaries at $2,000 annually beginning in 2025. This cap directly benefits patients taking high-cost branded drugs like Eliquis, particularly those who previously hit the coverage gap ("donut hole") and faced full retail costs [15].

Practical Checklist Before Your ChristianaCare Appointment

Arriving at your appointment with these items speeds up the coverage process considerably:

• Your insurance card (both sides, including the pharmacy benefit card if separate)
• A list of all current medications, including supplements, to allow a drug interaction screen
• Your most recent serum creatinine or eGFR result if available (needed for correct dosing)
• Any prior authorization letters or denial letters from previous insurers
• Your diagnosis documentation (AF diagnosis date, ECG confirmation, DVT/PE imaging results)
• A note of your weight if you are near the 60 kg threshold for dose reduction

Bringing this information allows your ChristianaCare prescriber to submit a complete, accurate PA at the first attempt, cutting the typical 3 to 7-day back-and-forth with the insurer.